Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Mikkael A SekeresJustin WattsAtanas RadinoffMontserrat Arnan SangermanMarco CerranoPatricia Font LopezJoshua F ZeidnerMaria Diez CampeloCarlos GrauxJane LiesveldDominik SelleslagNikolay TzvetkovRobert J FramDan ZhaoJill BellSharon FriedlanderDouglas V FallerLionel AdèsPublished in: Leukemia (2021)